ERBB2 and breast cancer: Altogether, our data indicate that LINC00589 expression is downregulated in trastuzumab-resistant breast cancer and correlates with patient survival, suggesting that LINC00589 may be a valuable diagnostic marker for discriminating trastuzumab responders and a prognostic marker for predicting the survival of HER2-positive breast cancer patients.